Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT04854980
Official study title

Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology Patients

Study summary

To explore the immune response to the COVID-19 vaccine in cancer patients and compare to the general population.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedBlood Sample

The study team can explain what participation involves.

Who it may be forCovid19 · Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 30, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?University of Rochester

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
University of Rochester
Interventions being studied
Other: Blood Sample
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Subjects are between 50 and 75 years of age;
  • Have not had known or suspected infection with SARS-CoV-2 at any time;
  • Subjects must fall into one of the following subsets of cancer patients:
  • Localized prostate cancer on radiotherapy or have completed radiotherapy in the last three months
  • Prostate cancer on androgen-deprivation therapy for biochemical recurrence
  • Colon cancer on adjuvant chemotherapy for stage III disease
  • CLL on a BTK inhibitor as a first-line single agent for at least 3 months
  • Melanoma patients on adjuvant immunotherapy with PD-1 checkpoint inhibitors for at least 3 months
  • Have received both doses of SARS-CoV-2 mRNA-1273 vaccine with proof of vaccination or are scheduled to do so;
  • Have at least a one-year life expectancy;
  • Prior radiation therapy is allowed, as long as it was completed more than 6 months prior to vaccination
Reasons someone may not be able to joinExclusion criteria
  • Subjects have a known hypersensitivity to a vaccine component;
  • Have had known or suspected infection with SARS-CoV-2 at any time;
  • Are organ transplant recipient on immunosuppression;
  • Had received or are scheduled to receive a live virus vaccine in the period from 4 weeks prior to Dose 1 through 28 days post second dose;
  • Had received or are scheduled to receive an inactivated vaccine in the period ranging from 7 days prior to Dose 1 through 7 days post second dose;
  • Received high-dose corticosteroids at any time after receiving the vaccine;
  • Are unable to give informed consent;
  • Are receiving treatment for CLL with another agent (such as rituximab) in addition to a BTK inhibitor

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of RochesterRochester, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 30, 2025. Always confirm current availability with the study team.

View original record ↗